Leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of aging and our search for interventions.
Adam Antebi
Director at the Max Planck Institute for Biology of Ageing, Germany
Dr Antebi received his PhD from Massachusetts Institute of Technology, and performed his post-doctoral research at the Johns Hopkins University. He first worked as an Independent Group Leader at the Max Planck Institute for Molecular Genetics, Berlin, and then as an Associate Professor at Baylor College of Medicine, Houston.In 2008, he became a founding Director of the Max Planck Institute for Biology of Ageing, Cologne. His research has focused on unravelling regulatory mechanisms governing animal longevity, and has discovered that hormone driven developmental clocks regulate life span and that small nucleoli are a conserved cellular hallmark of longevity.
Nir Barzilai
Albert Einstein College of Medicine, USA
Dr. Nir Barzilai is the founding director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine of Yeshiva University (Einstein). He also directs the Longevity Genes Project, a genetics study of over 600 families of centenarians and their children. The participants are all Ashkenazi Jews, a group selected for their genetic homogeneity, which makes it easier to identify significant genetic variations. Dr. Barzilai found that many of the centenarians had very high levels of HDL, or the "good cholesterol." Dr. Barzilai is also co-founder of CohBar, Inc., a biotechnology company developing mitochondria based therapeutics to treat diseases associated with aging.

Dr. Barzilai discovered several "longevity genes" in humans that were validated by others. These include variants in genes involved in cholesterol metabolism (CETP and APOC3), metabolism (ADIPOQ and TSHR) and growth (IGF1R). These genes appear to protect centenarians against major age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes and dementia.
Anne Brunet
Stanford, USA
Anne Brunet is the Michele and Timothy Barakett Endowed Professor and the co-director of the Paul F. Glenn Laboratories for the Biology of Aging at Stanford University. Her lab studies mechanisms of aging and longevity. Brunet received her BS in Biology, summa cum laude, in 1992 from Ecole Normale Supérieure, Paris, France. She immediately began a PhD in the lab of Jacques Pouysségur at the University of Nice, France, which she completed in 1997. Between 1998 and 2003, she did her postdoctoral work at Harvard Medical School in Michael E. Greenberg's laboratory. She has been a professor at Stanford since 2004. She is a member of the Editorial Board for Genes & Development. Brunet's lab works on discovering lifespan-regulating genes and their interactions with the environment. Next, she studies how conserved 'pro-longevity genes' (e.g. FOXO transcription factors) regulate longevity in mammals, the regenerative potential of stem cells, and the nervous system. She uses mammalian tissue culture and C. elegans as model systems to study longevity pathways, dietary restriction, and epigenetic (chromatin-state) regulation of longevity by the environment. In addition, she is developing the extremely short-lived African killifish N. furzeri as a new vertebrate model for aging.
Joseph A. Baur
University of Pennsylvania, USA
Joseph Baur earned his Ph.D. from the University of Texas Southwestern Medical Center in Dallas, Texas, where he studied mechanisms that limit the lifespan of cultured human cells under Drs. Jerry Shay and Woody Wright. He then moved to Harvard Medical School where he trained as a postdoctoral fellow with Dr. David Sinclair. There he developed a strong interest in the regulation of aging and metabolism by sirtuins, a conserved class of enzymes that require nicotinamide adenine dinucleotide (NAD) as a co-substrate. His lab currently studies metabolic and signaling pathways by which nutrient intake can influence longevity, with a particular emphasis on NAD and mTOR.
Luigi Ferrucci
National Institute on Aging
Dr. Luigi Ferrucci is a geriatrician and an epidemiologist who conducts research on the causal pathways leading to progressive physical and cognitive decline in older persons. He has made major contributions in the design of many epidemiological studies conducted in the U.S. and in Europe. Dr. Ferrucci received a Medical Degree and Board Certification in 1980, Board Certification in Geriatrics in 1982 and Ph.D. in Biology and Pathophysiology of Aging in 1998 at the University of Florence, Italy. Between 1985 and 2002 he was Chief of Geriatric Rehabilitation at the Department of Geriatric Medicine and Director of the Laboratory of Clinical Epidemiology at the Italian National Institute of Aging. In September 2002, he became the Chief of the Longitudinal Studies Section at NIA. From 2002 to 2014 he was the Director of the Baltimore Longitudinal Study on Aging. Dr. Ferrucci is currently the Scientific Director of NIA, since May 2011.
Evandro Fei Fang
University of Oslo, Norway
The Evandro F. Fang group are investigating the molecular mechanisms of human aging, and age-predisposed neurodegeneration, especially Alzheimer's disease (AD). After finished his Ph.D. training in Biochemistry with Chair Professor Tzi Bun Ng at The Chinese University of Hong Kong in 2012, he started a 5-year postdoctoral fellowship at the National Institute on Aging USA with Professor Vilhelm Bohr on DNA repair and mitophagy in accelerated ageing, and with Professor Mark Mattson on strategies to improve neuronal resilience. In September 2017, he established his independent laboratory at The University of Oslo, Norway (https://evandrofanglab.com/). The Fang laboratory is focusing on the molecular mechanisms of how cells clear their damaged and aged mitochondria, a process termed "mitophagy", as well as the roles of the NAD+-mitophagy axis in healthy ageing and AD inhibition. NAD+ is a fundamental molecule in life and health and decreases in ageing (both biological and pathological) and AD. He is fascinated with and actively engaged in moving his laboratory findings to translational applications, as involved in 5+ NAD+-based clinical trials, with the overarching goal to establish novel and safe biological approaches to promote longer and healthier human lives.

He has published over 70 papers in international peer-reviewed journals including papers in Cell, Cell Metabolism, Nature Reviews MCB, and Nature Neuroscience. He has received several awards including The NIH Fellows Award for Research Excellence 2014, 2015, an awardee of the Butler-Williams Scholar on Aging 2016 (USA), a FRIMEDBIO Young Research Talent 2017(Norway), a finalist of the 2017 ERC Starting grant, an awardee of the Norwegian Cancer Society Pink Ribbon 2020 grant, and DKNVS 'scientific award to young scientist in the natural sciences for 2020 (DKNVS' vitenskapelige pris til yngre forskere innen naturvitenskap for 2020) by The Royal Norwegian Society of Sciences and Letters.

He is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing network (NO-Age, www.noage100.com), the Norwegian National anti-Alzheimer's disease Network (NO-AD, www.noad100.com), and the Hong Kong-Nordic Research Network.
Vadim Gladyshev
Harvard Medical School, USA
Vadim Gladyshev is a Professor of Medicine at Harvard Medical School, Director of the Center for Redox Medicine at Brigham and Women's Hospital, and Associate Member of the Broad Institute. Dr. Gladyshev's lab focuses on studying aging, rejuvenation and lifespan control using a combination of experimental and computational approaches. He has published more than 400 articles. Dr. Gladyshev is the recipient of NIH Pioneer, Transformative and Eureka awards and is an elected member of the National Academy of Sciences, USA.
Vera Gorbunova
University of Rochester, USA
Vera Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Aging Research Center. Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. Dr. Gorbunova earned her B.Sc. degrees at Saint Petersburg State University, Russia and her Ph.D. at the Weizmann Institute of Science, Israel. Dr. Gorbunova pioneered comparative biology approach to study aging. She also investigates the role of genomic instability and transposable elements in aging and disease. Recently she demonstrated that LINE1 elements trigger innate immune response that drives age-related sterile inflammation. She has more than 100 publications including publications in high profile journals such as Nature, Science and Cell. Her work received awards of from the Ellison Medical Foundation, the Glenn Foundation, American Federation for Aging Research, and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, prize for research on aging from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center.
Brian Kennedy
National University of Singapore, Singapore
Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Programme, and (3) the Asian Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.

From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell. Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.
Valter Longo
USC Davis School of Gerontology, USA
Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles, one of the leading centers for research on aging and age-related disease. Dr. Longo is also the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy.

Dr. Longo studied biochemistry as an undergraduate at the University of North Texas, and received his PhD in Biochemistry from UCLA, where he worked under calorie restriction guru Roy Walford, MD. He completed his postdoctoral training in neurobiology with longevity pioneer, Caleb Finch, PhD. He also received extensive training in immunology, endocrinology, microbiology, genetics, molecular biology, and pathology.

His studies focus on the fundamental mechanisms of aging in simple organisms and mice and on how these mechanisms can be translated to humans. The Longo laboratory has identified some of the key genetic pathways that regulate aging in simple organisms and has demonstrated that the inactivation of such pathways can reduce the incidence or progression of multiple diseases in mice and humans. His laboratory has also developed both dietary and genetic interventions that protect normal cells while sensitizing cancer cells to chemotherapy— interventions now being tested in many US and European hospitals.

Andrea B. Maier
Oon Chiew Seng Professor in Medicine and Functional Ageing, National University of Singapore, Professor of Gerontology Vrije Universiteit Amsterdam, The Netherlands
Professor Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. From 2016 to early 2021 Professor Maier has served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continues her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier's research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees. She currently is the President of The Australian and New Zealand Society for Sarcopenia and Frailty Research.
Julia von Maltzahn
Research group leader
Leibniz Institute On Aging/Fritz Lipmann Institute (FLI)
Dr. Julia von Maltzahn has been a Group leader at the Leibniz Institute on Aging, Fritz-Lipmann Institute (FLI), Jena, Germany since October 2013 after working as a Postdoctoral fellow in the laboratory of Prof. Dr. Michael Rudnicki at the Sprott Center for Stem Cell Research in Ottawa, Canada. Her research focuses on intrinsic and extrinsic changes in muscle stem cells which occur during aging and how this affects regeneration of skeletal muscle.
Alexey Moskalev
School of Systems Biology, George Mason University (GMU), Fairfax, VA, USA
Prof. Alexey Moskalev is a Corresponding member of Russian Academy of Sciences, Doctor of Biology, the Head of the Laboratory of Geroprotective and Radioprotective Technologies in the Institute of Biology of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, the Head of the Department of Ecology of the Syktyvkar State University named after Pitirim Sorokin, the Head of the Laboratory of Genetics of Aging and Longevity in the Moscow Institute of Physics and Technology
Thomas Rando
Stanford, USA
Thomas A. Rando is an American neurologist. Rando is best known for his research on basic mechanisms of stem cell biology and the biology of aging, as well as for contributions to the study of the muscular dystrophies and the emerging field of regenerative rehabilitation. He is a Professor of Neurology and Neurological Sciences at Stanford University School of Medicine, where he is founding director of the Glenn Center for the Biology of Aging. Rando is also Chief of Neurology at the VA Palo Alto Health Care System.
Björn Schumacher
Director, Institute for Genome Stability in Aging and Disease
University of Cologne
Since 2013, Björn Schumacher is full professor and director of the Institute
for Genome Stability in Ageing and Diseases (IGSAD) at the CECAD
Research Centre of the University of Cologne. He received his PhD at the
Max Planck Institute for Biochemistry in Munich and conducted his
postdoctoral research as EMBO and Marie Curie fellow at the Erasmus
Medical Centre in Rotterdam. Professor Schumacher is President of the
German Society for DNA Repair (DGDR), co-Director of the Minerva Center
of the Biological Mechanisms of Healthy Ageing at Bar-Ilan University (IL),
and between 2014 and 2020 served as President of the German Society
for Ageing Research (DGfA). He was awarded with the Eva Luise Köhler
Research Prize, the Innovation Prize of the State of North Rhine-
Westphalia, the European Research Council (ERC) starting grant,
coordinated the FP7 Marie Curie initial training network on chronic DNA
damage in ageing (CodeAge) and serves on several editorial boards. His
research interest focuses on the molecular mechanisms through which
DNA damage contributes to cancer development and ageing-associated
diseases. Employing the C. elegans system and mammalian disease
models, his group uncovered cell-autonomous and systemic responses
through which the organism adapts to accumulating DNA damage with
ageing. Through the understanding of the basic mechanisms of genome
instability-driven ageing, Schumacher aims to contribute to the
development of future strategies to prevent ageing-associated diseases.
Manuel Serrano
Principal Investigator at Altos Labs, Cambridge Institute of Science, Cambridge, UK
Manuel Serrano obtained his PhD in 1991 in Madrid, Spain. In 1993, as a postdoctoral researcher in the laboratory of David Beach at Cold Spring Harbor Lab, NY, USA, he reported the discovery of the gene p16, a key anti-cancer gene and a inducer of cellular senescence. From 1997 to 2022, Serrano developed his career in Spain, initially in Madrid and since 2017 in Barcelona. His laboratory has made important contributions to the fields of cellular senescence and cellular reprogramming. In 2023, Serrano joined Altos Labs in Cambridge, UK, where he continues investigating on senescence and reprogramming with the aim understand the process of aging and its associated diseases.
John Speakman
Shenzhen Institutes of Advanced Technology in Shenzhen, China
John Speakman is a Professor at the Shenzhen Institutes of Advanced Technology in Shenzhen, China and also at the University of Aberdeen in Scotland, UK. He has been working on energy balance and obesity for more than 40 years. During that time he published over 600 scientific papers including 11 in Nature/Science, and was featured twice on the cover of Nature. He is a foreign member of the US National Academy of Sciences, an academician of the Chinese National Academy of Sciences and a Fellow of the UK Royal Society. In 2020 he was awarded the US Obesity Society TOPS award (their premier research award) and was also awarded the Osborne-Mendel prize by the American Society of Nutrition for basic research.
Yousin Suh
Columbia University, USA
Yousin Suh, Ph.D., is the Charles and Marie Robertson of Reproductive Sciences in Obstetrics and Gynecology, Professor of Genetics and Development, and Director of Reproductive Aging in Obstetrics and Gynecology in the Vagelos College of Physicians and Surgeons at Columbia University. She investigates the (epi)genetic component that underlies the interface of intrinsic aging and disease. The approach she follows is based on the identification of (epi)genome sequence variants associated with age-related disease risk or its opposite, i.e., an unusual resistance to such disease. For this purpose her target populations are either cohorts of middle-aged individuals followed longitudinally for signs of all major age-related diseases, or cohorts of extremely long-lived individuals who managed to ward off such diseases. To tackle the key problem of identifying the functional impact of any observed association, she applies specific functional tests, including in silico modeling, cell culture assays and mouse models. Discoveries thus far made include novel, rare alleles associated with extreme longevity, sirtuin variants that confer risk for heart disease, functional non-coding variants in the gene desert Chr. 9p21 locus underlying multiple age-related diseases, longevity-associated miRNAs, and epigenetic signatures of cellular senescence. Her contributions in the field have been recognized by the Glenn Award for Research in Biological Mechanisms of Aging. She has organized numerous international symposiums on functional genomics of aging, is on the Editorial Boards of numerous Journals including PLoS Genetics and Aging Cell as an Associate Editor, and participates in advisory committee members for several research institutions and companies.
Dario Valenzano
Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany
Friedrich Schiller University of Jena, Germany
Dario Riccardo Valenzano studied neuroscience at the Scuola Normale Superiore in Pisa (Italy) and did a postdoc at Stanford University. He is full professor at the Friedrich Schiller University in Jena (Germany) and Senior Group Leader at the Leibniz Institute on Aging (Fritz-Lipmann Institute), where he coordinates the research focus Microbiome and Aging.
The Valenzano research team studies the genomic basis of short/long lifespan across species and investigates the role of commensal gut microbes during aging. Their main model system is the naturally short-lived turquoise killifish (Nothobranchius furzeri), which they study in the lab as well as in their natural habitat in the African savannah.
Eric Verdin
Buck Institute, USA
Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a professor of medicine at University of California, San Francisco.

Dr. Verdin studies how metabolism, diet, and small molecules regulate the activity of HDACs and sirtuins, and thereby the aging process and its associated diseases, including Alzheimer's. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1 percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of National Institute on Drug Abuse at the National Institutes of Health.
Tony Wyss-Coray
Stanford, USA
The Wyss-Coray research team studies brain aging and neurodegeneration with a focus on age-related cognitive decline and Alzheimer's disease. The lab is following up on earlier discoveries which showed circulatory blood factors can modulate brain structure and function and factors from young organisms can rejuvenate old brains. Current studies focus on the molecular basis of this systemic communication with the brain by employing a combination of genetic, cell biology, and proteomics approaches in model organisms and humans.
The lab is part of the Glenn Center for Aging at Stanford University, the Stanford Neurosciences Institute's Brain Rejuvenation Project, The NIH Alzheimer's Disease Research Center, and it is funded by the American Heart Association / Allen Initiative, the National Institute on Aging, and the NOMIS Foundation.